Case-Based Roundtable Meetings Spotlight: December 2, 2022

During a Targeted Oncology case-based roundtable event, J. Paul Monk, MD, discussed dosing and sequencing considerations for the use of cabazitaxel for patients with metastatic castration-resistant prostate cancer.

During a Targeted Oncology Evolving Paradigms roundtable, Sara A. Hurvitz, MD, discussed elacestrant and other investigational agents for patients with breast cancer.

During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the case of a patient with a 4.5-cm Liver Imaging Reporting and Data System category 5 (LR-5) hepatic mass, Crohn disease, and cirrhosis.

During a Targeted Oncology case-based roundtable event, Hana Safah, MD, discussed chronic graft-vs-host disease in terms of diagnosis, phases, risk assessment, and treatment options.

During a Targeted Oncology case-based roundtable event, Rana McKay, MD, and participants discussed the case of a patient with previously untreated advanced renal cell carcinoma with favorable risk status.

During a Targeted Oncology case-based roundtable event, Matthew Matasar, MD, MS, discussed the case of a patient with diffuse large B-cell lymphoma who relapsed 18 months following frontline combination therapy.

During a Targeted Oncology case-based roundtable event, Patrick Forde, MBBCh, discussed the use of the regimen consisting of nivolumab, ipilimumab, and 2 cycles of chemotherapy for non–small cell lung cancer.

At a live virtual event, Priyanka Sharma, MD, discussed the treatment options for patients with metastatic breast cancer who develop triple-negative breast cancer.